Modelling the impact of acute infection dynamics on the accumulation of HIV-1 mutations

Journal of Theoretical Biology

Volumn 279, Issue 1, 2011, Pages 44-54

  Shiri, Tinevimbo ^a,b   Welte, Alex ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Branching process; Diversity; Effective reproductive number; PrEP; Vaccine

Indexed keywords

EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TENOFOVIR DISOPROXIL;

DRUG RESISTANCE; GENOME; HUMAN IMMUNODEFICIENCY VIRUS; MODELING; MUTATION; VACCINE;

ANTIVIRAL RESISTANCE; ARTICLE; CHRONICITY; EARLY INTERVENTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPROPHYLAXIS; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MATHEMATICAL MODEL; MICROBIAL DIVERSITY; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RISK REDUCTION; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; WILD TYPE;

AIDS VACCINES; BASIC REPRODUCTION NUMBER; COMPUTER SIMULATION; HIV INFECTIONS; HIV-1; MODELS, BIOLOGICAL; MUTATION; STOCHASTIC PROCESSES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953252832     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.03.011     Document Type: Article

References (57)

1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., et al. Effectiveness and safety of Tenofovir Gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329(5996):1168-1174.
2. Abrahams M.R., Anderson J.A., Giorgi E.E., et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J. Virol. 2009, 83(8):3556-3567.
3. Anderson R.M., May R.M. Infectious Diseases of Humans 1991, Oxford University Press, Oxford.
4. Asquith B., Edwards C.T.T., Lipsitch M., McLean A.R. Inefficient cytotoxic T lymphocyte mediated killing of HIV-1-infected cells in vivo. PLoS Biol. 2006, 4(4):e90. 10.1371/journal.pbio.0040090.
5. Bonhoeffer S., Nowak M.A. Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. Biol. Sci. 1997, 264(1382):631-637.
6. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., Nguyen P.L., Khoruts A., Larson M., Haase A.T., Douek D.C. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004, 200:749-759.
7. Chun T.W., Engel D., Berrey M.M., Shea T., Corey L., Fauci A.S. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 1998, 95(15):8869-8873.
8. Dinoso J.B., Kim S.Y., Wiegand A.M., et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. 2009, 106(23):9403-9408.
9. Domingo E., Menendez-Arias L., Holland J.J. RNA virus fitness. Rev. Med. Virol. 1997, 7(2):87-96.
10. Fiebig W.E., Wright J.D., Rawal D.B., et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871-1879.
11. Finzi D., Blankson J., Siliciano J.D., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5:512-517.
12. Garcia-Lerma G.J., Otten R.A., Qari S.H., et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008, 5:e28.
13. Goonetilleke N., Liu M.K.P., Salazar-Gonzalez J.F., et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 2009, 206(6):1253-1272.
14. Granich R.M., Gilks C.F., Dye C., et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373(9657):48-57.
15. Griffin, J.T., Garske, T., Ghani, A.C., 2010. Joint estimation of the basic reproduction number and generation time parameters for infectious disease outbreaks. Biostatistics, page [Epub ahead of print]. doi:. http://10.1093/biostatistics/kxq058.
16. Haase A.T. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Ann. Rev. Immunol. 1999, 17:625-656.
17. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 2005, 5:783-792. 10.1038/nature08757.
18. Haeno H., Iwasa Y. Probability of resistance evolution for exponentially growing virus in the host. J. Theor. Biol. 2007, 246(2):323-331.
19. Hansasuta P., Rowland-Jones S.L. HIV-1 transmission and acute HIV-1 infection. Br. Med. Bull. 2001, 58:109-127.
20. Ho D.D. Time to hit HIV, early and hard. N. Engl. J. Med. 1995, 333(7):450-451.
21. Holmberg S.D., Palella F.J., Lichtenstein K.A., Havlir D.V. The case for earlier treatment of HIV infection. Clin. Infect. Dis. 2004, 39:1699-1704.
22. Iwasa Y., Michor F., Nowak M.A. Evolutionary dynamics of escape from biomedical intervention. Proc. R. Soc. Lond. B 2003, 270:2573-2578.
23. Iwasa Y., Michor F., Nowak A.M. Evolutionary dynamics of invasion and escape. J. Theor. Biol. 2004, 226:205-214.
24. Johnson J.A., Li J.-F., Wei X., Lipscomb J., Irlbeck D., et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment naive populations and associate with reduced treatment efficacy. PLoS Med. 2008, 5(7):e158. 10.1371/journal.pmed.0050158.
25. Joos B., Trkola A., Fischer M., et al. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J. Virol. 2005, 79(14):9026-9037.
26. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 2008, 105:7552-7557.
27. Kimmel M., Axelrod E.D. Branching Processes in Biology 2001, Springer-Verlag, New York.
28. Lee H.Y., Perelson A.S., Park S.-C., Leitner T. Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput. Biol. 2008, 4(12):e1000240. 10.1371/journal.pcbi.1000240.
29. Lee H.Y., Giorgi E.E., Keele F.B., Gaschen B., Athreya S.G., et al. Modeling sequence evolution in acute HIV-1 infection. J. Theor. Biol. 2009, 261:341-360.
30. Letvin L.N., Mascola R.J., Sun Y., Gorgone A.D., Buzby P.A., Xu L., Yang Z., Chakrabarti B., Rao S.S., Schmitz E.J., Montefiori C.D., Barker R.B., Bookstein L.F., Nabel J.G. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312:1530-1533.
31. Liner K.J., Hall C.D., Robertson K.R.R. Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J. Neurovirol. 2007, 13(4):291-304. 10.1080/13550280701422383.
32. Little S.J., McLean A.R., Spina C.A., Richman D.D., Havlir D.V. Viral dynamics of acute HIV-1 infection. J. Exp. Med. 1999, 190:841-850.
33. Little S.J., Holte S., Routy J.P. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 2002, 347:385-394.
34. Lori F., Jessen H., Lieberman J., Finzi D., Rosenberg E., Tinelli C., Walker B., Siliciano R.F., Lisziewicz J. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J. Infect. Dis. 1995, 180(6):1827-1832.
35. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 1995, 69(8):5087-5094.
36. Markowitz M., Louie M., Hurley A., et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 2003, 77:5037-5038.
37. Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
38. McMichael J.A., Borrow P., Tomaras D.G., Goonetilleke N., Haynes F.B. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 2010, 10:11-23.
39. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., Boden D., Racz P., Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 2004, 200:761-770.
40. Mellors J., Palmer S., Nissley D., et al. Low frequency non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI mutations. Antivir. Ther. 2003, 8:S150.
41. Nowak M.A., Lloyd A.L., Vasquez G.M., Wiltrout T.A., Wahl L.M., Bischofberger N., Williams J., Kinter A., Fauci A.S., Hirsch V.M., Lifson J.D. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 1997, 71(10):7518-7525.
42. Nowak M.A., Sebastian B., Shaw G.M., May R.M. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 1997, 184(2):203-217.
43. Olofsson P., Shaw A.C. Exact sampling formulas for multi-type Galton-Watson processes. Math. Biol. 2002, 45:279-293.
44. Peterson L., Taylor D., Roddy R., et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin. Trials 2007, 2:e27.
45. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361(23):2209-2220.
46. Ribeiro R.M., Bonhoeffer S. A stochastic model for primary HIV infection: optimal timing of therapy. AIDS 1999, 13:351-357.
47. Ribeiro R.M., Bonhoeffer S., Nowak M.A. The frequency of resistant mutant virus before antiviral therapy. AIDS 1998, 12:461-465.
48. Ribeiro R.M., Qin L., Chavez L.L., Li D., Self S.G., Perelson A.S. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J. Virol. 2010, 84(12):6096-6102. 10.1128/JVI.00127-10.
49. Richman D.D. HIV chemotherapy. Nature 2001, 410:995-1001.
50. Shankarappa R., Margolick J.B., Gange S.J., et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 1999, 73(12):10489-10502.
51. Stilianikis N.I., Boucher C.A.B., De-Jong M.D., Van Leeuwen R., Schuurman R., De-Boer R. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. J. Virol. 1997, 71(1):161-168.
52. Strain M.C., Little S.J., Daar E.S., Havlir D.V., Gunthard H.F., Lam R.Y., Daly O.A., Nguyen J., Ignacio C.C., Spina C.A., Richman D.D., Wong J.K. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 2005, 191(9):1410-1418.
53. Tebit D.M., Nankya I., Arts E.J., Gao Y. HIV diversity, recombination and disease progression: how does fitness fit into the puzzle?. AIDS Rev. 2007, 9(2):75-87.
54. Tomaras G.D., Yates N.L., Liu P., et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008, 82(24):12449-12463. 10.1128/JVI.01708-08.
55. Wilson N.A., Reed J., Napoe G.S., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 2006, 80(12):5875-5885.
56. Wong S.B.J., Siliciano R.F. Biology of early infection and impact on vaccine design. AIDS Vaccine Development: Challenges and Opportunities 2007, 17-22. Caister Academic, UK.
57. Wood N., Bhattacharya T., Keele B.F., Giorgi E., Liu M., et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathogens 2009, 5(5):e1000414. 10.1371/journal.ppat.1000414.